The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

• Published in: Haematologica (Roma) Vol. 109; no. 10; pp. 3379 - 3382
• Main Authors: Danilov, Alexey V., Flinn, Ian W., Davids, Matthew S., Gregory, Beth, Bentur, Ohad, Sidransky, David, Brown, Jennifer R.
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.10.2024; Ferrata Storti Foundation
• Subjects: Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Female; Humans; Isoquinolines - administration & dosage; Isoquinolines - therapeutic use; Letter to the Editor; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors - therapeutic use; Purines - therapeutic use; Recurrence; Treatment Outcome